TG Therapeutics Inc.
Commercial-stage biopharma TG Therapeutics targets B‑cell mediated diseases, with BRIUMVI for relapsing MS and a 4‑agent pipeline—Ublituximab, TG‑1701 BTK inhibitor, TG‑1801 bispecific antibody—plus licensure of umbralisib.
Headquarters: United States (USA)
- Website: Visit Site 🔗
- Type: Corporation
Company Profile
- Sector: Manufacturing
- Industry: Medical Equipment Manufacturing
- Employees: 374
- HQ: Morrisville
Unlock the full potential.
Upgrade
Get access to Relative P/E Ratio Valuation Histogram.